Amgen’s BLINCYTO (blinatumomab, BiTE) Receives EU Expanded approval for pediatric 2L+ B-cell-ALL

 Amgen’s BLINCYTO (blinatumomab, BiTE) Receives EU Expanded approval for pediatric 2L+ B-cell-ALL

Amgen’s BLINCYTO (blinatumomab, BiTE) Receives EU Expanded approval for pediatric 2L+ B-cell-ALL

Shots:
  • This approval is based on P-I/II ‘205 study for the treatment of pediatric patients aged 1-17yr with Philadelphia chromosome-neg CD19 +ve (r/r) B-cell precursor ALL
  • P-I/II ‘205 study (N=93) administering dose (5 ,15 μg/m2/day on days 1-7 day, 8-28 for cycle 1, followed by two weeks off, and 15 μg/m2/day on days 1-28 two weeks off for subsequent cycles
  •  Results: median Age is eight yrs. (range: 7mos to 17yrs); CR/CR+partial hematologic recovery (n=20/70,28.6%); (17/20, 85%) occurring within the first cycle

Click here to read full press release/ article | Ref: Amgen | Image:  2Vote

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post